Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae - PubMed (original) (raw)

Comparative Study

doi: 10.1007/s10863-012-9421-8. Epub 2012 Feb 23.

Affiliations

Comparative Study

Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae

Paweł Lis et al. J Bioenerg Biomembr. 2012 Feb.

Abstract

We have investigated the cytotoxicity in Saccharomyces cerevisiae of the novel antitumor agent 3-bromopyruvate (3-BP). 3-BP enters the yeast cells through the lactate/pyruvate H(+) symporter Jen1p and inhibits cell growth at minimal inhibitory concentration of 1.8 mM when grown on non-glucose conditions. It is not submitted to the efflux pumps conferring Pleiotropic Drug Resistance in yeast. Yeast growth is more sensitive to 3-BP than Gleevec (Imatinib methanesulfonate) which in contrast to 3-BP is submitted to the PDR network of efflux pumps. The sensitivity of yeast to 3-BP is increased considerably by mutations or chemical treatment by buthionine sulfoximine that decrease the intracellular concentration of glutathione.

PubMed Disclaimer

References

    1. Cancer Res. 2002 Jul 15;62(14):3909-13 - PubMed
    1. Annu Rev Biochem. 1993;62:385-427 - PubMed
    1. Appl Environ Microbiol. 1987 Mar;53(3):509-13 - PubMed
    1. Annu Rev Biochem. 1989;58:137-71 - PubMed
    1. Clin Microbiol Rev. 2009 Apr;22(2):291-321, Table of Contents - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources